Trial Search Results

Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns

In South Africa, healthy term newborns are usually discharged early (<72 hours after delivery). Many studies have shown that hospital readmission rates have increased with this practice, and jaundice or hyperbilirubinemia is the most common cause of readmission of newborns. Peak serum bilirubin levels usually occur on postnatal days 3-5, by when many have already been discharged putting the infant at increased risk of severe hyperbilirubinemia. Severe neonatal jaundice still constitutes an important cause of neonatal mortality and morbidity in Africa. Screening all newborns for the risk of severe hyperbilirubinemia before hospital could help in early identification of hyperbilirubinemia and early intervention and potentially prevent unwanted consequences like bilirubin induced neurological dysfunction. However, there are conflicting recommendations on the use of universal transcutaneous bilirubin screening for jaundice in all newborns before hospital discharge.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Stellenbosch

Collaborator: Stanford University

Stanford Investigator(s):

Intervention(s):

  • Device: Transcutaneous bilirubin screening
  • Other: Standard care (Visual inspection)

Phase:

N/A

Eligibility


Inclusion Criteria:

   - All newborns ≥ 35 wks gestational age and ≥ 1800g

   - Babies who who are < 72 hours of life

Exclusion Criteria:

   - Prior use of phototherapy

   - Major congenital anomaly

   - Babies born < 35 wks gestational age or < 1800g

Ages Eligible for Study

N/A - 72 Hours

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting